New Oral Antibiotic Offers Breakthrough Treatment for Drug-Resistant Gonorrhoea

Phase-three trial confirms gepotidacin’s effectiveness against resistant strains, providing a promising alternative to injection-based therapies.

Gepotidacin, an oral antibiotic, has been validated in a phase-three trial as an effective treatment for gonorrhoea, including resistant strains.
The trial, involving 622 patients, demonstrated that gepotidacin is as effective as the current standard treatment of ceftriaxone and azithromycin.
This marks the first major advancement in gonorrhoea treatment in over 30 years, addressing the urgent need for solutions as drug-resistant cases rise globally.
The pill-based treatment eliminates the need for injections, potentially improving patient experiences and reducing healthcare resource demands.
Researchers caution that further studies are needed to assess the drug's effectiveness across diverse populations and infection sites beyond urogenital cases.